Amyloid β-peptide (1-40) rat |
Catalog No.GC35335 |
Amyloid β-peptide (1-40) rat is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 144409-98-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Eight-week-old male Sprague-Dawley rats (n=14) weighing 200 to 220 g are used in this study. The rats are housed in plastic cages with food and water supplied ad libitum, and are maintained on a 12-h light/dark cycle at room temperature (21 to 23°C). 14 rats are randomly divided into two groups: (1) Milli-Q water-injected rats serve as the control group and (2) fibrillar neurotoxic Amyloid β-peptide (1-40) (rat) injected rats serve as the Amyloid β-peptide (1-40) (rat) group. Fibrillar Amyloid β-peptide (1-40) (rat) or Milli-Q water (2 μL) is injected at a flow rate of 0.5 μL/min. Following injection, the needle is maintained in place for 5 min prior to its slow extraction. A second injection is also administered at the same coordinate in the opposite hemisphere. The behavioral performances of animals are assessed by the step-down passive avoidance test and Morris water maze test[1]. |
References: [1]. Shi X, et al. Rat hippocampal proteomic alterations following intrahippocampal injection of amyloid betapeptide (1-40). Neurosci Lett. 2011 Aug 15;500(2):87-91. |
Amyloid β-peptide (1-40) (rat) is the prone-to-aggregation product of amyloid precursor protein proteolytic cleavage, and is the major constituent of senile plaques observed in the brain of Alzheimer's disease. The Amyloid β-peptide (1-40) (rat)-treated rats require longer to find the platform hidden under the water. In the visible platform test, the latency for each group is similar (20.56±11.31 s in control and 14.68±9.97 s in Amyloid β-peptide (1-40) (rat) group, p=0.304). Among these tested proteins, 6 ones are significantly up-regulated and 7 ones significantly down-regulated in Amyloid β-peptide (1-40) (rat) group comparing with the control. Tubulin β chain is significantly down-regulated in Amyloid β-peptide (1-40) (rat) group (p=0.014) when compare with control. Similar changes are also observed for ATP synthase β subunit (p=0.010) and synapsin Ib between Amyloid β-peptide (1-40) (rat) and control groups, but not significantly for synapsin Ib (p=0.295)[1].
[1]. Shi X, et al. Rat hippocampal proteomic alterations following intrahippocampal injection of amyloid betapeptide (1-40). Neurosci Lett. 2011 Aug 15;500(2):87-91.
Cas No. | 144409-98-3 | SDF | |
Formula | C190H291N51O57S | M.Wt | 4233.76 |
Solubility | Soluble in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.2362 mL | 1.181 mL | 2.362 mL |
5 mM | 0.0472 mL | 0.2362 mL | 0.4724 mL |
10 mM | 0.0236 mL | 0.1181 mL | 0.2362 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *